secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2026-07-17T20:01:17+00:00
Accession:  0001193125-26-307767
Event type: litigation
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon supplements proxy with $700M synergy estimate; shareholder lawsuit seeks to delay merger vote
--------------------------------------------------------------------------------

- Shareholder lawsuit filed July 6 in NJ Superior Court alleges proxy disclosures are materially incomplete and misleading.
- Company voluntarily supplements proxy with preliminary cost synergy estimate of ~$700M from Sun Pharma transaction.
- Provides financial projections: 2026E revenue $6,252M, Adj EBITDA $1,894M, unlevered FCF $1,010M.
- Net debt $7,530M, fully diluted shares ~284.9M as of April 24, 2026; LTM Adj EBITDA $1,832M.
- Special meeting of stockholders to vote on merger remains scheduled for July 23, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000119312526307767/0001193125-26-307767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000119312526307767/d88294d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-307767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer